Navigation Links
Use of Biomarkers in Clinical Trials for Drugs Outside of Oncology is Increasing

BURLINGTON, Mass., Nov. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while most of the biomarker-drug success stories are in oncology, biomarkers play a critical role in pharmaceutical development of chronic conditions, and their use in clinical trials of drugs outside of oncology is building. The Strategic Insights report entitled Driving Drug and Diagnostic R&D: The Influence of Biomarkers Beyond Oncology, finds that through biomarkers, upcoming chronic disease drugs will target new mechanisms of action, address niche subpopulations and fill the need for safer and more effective treatments. Biomarkers, when placed at the core of R&D programs, can reveal essential information about the drugs in development and/or the target populations.

According to the report, an analysis of ongoing clinical trials using biomarkers reveals a plethora of opportunities for drug R&D in a number of non-oncology therapy areas. Collectively, there are more clinical trials and deals over the last five years involving biomarkers for non-cancer indications than those focusing solely on cancer indications. For instance, all of AbbVie's trials using biomarkers are in non-cancer areas, as are more than half of all biomarker-focused trials sponsored by Merck, Roche, GlaxoSmithKline and Pfizer. While most active clinical trials involving biomarkers are in earlier phases, biomarkers in late-phase trials support label extension or evaluate long-term safety.

The report also explores how companies are capitalizing on the utility of biomarkers in the R&D programs in Alzheimer's disease, asthma, and type 2 diabetes.

"With the advances in biomarker research and in improved diagnostic imaging capabilities, the most notable impact of biomarker-involved drug development, outside of oncology, will be in central nervous system disorders," said Decision Resources Analyst Prachi Vora, M.P.H. "The incorporation of biomarker pathology in the inclusion criteria for a trial of Eli Lilly's solanezumab, an emerging therapy in Alzheimer's disease, is a key step toward mainstreaming biomarkers in CNS therapies."

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
2. Trial seeks improved lung-cancer screening by combining imaging and biomarkers
3. Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease
4. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
5. VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013
6. Spanish researchers design biomarkers for the detection of dengue and West Nile virus
7. NIH funds research to identify Parkinsons biomarkers
8. New AAN/ALS Association Clinical Fellow Will Pursue Immune Biomarkers
9. Epigenetic biomarkers may predict if a specific diet and exercise regimen will work
10. Novel biomarkers improve diagnosis in rheumatoid arthritis
11. Biomarkers Market: Epigenetic & MicroRNA Biomarkers Report
Post Your Comments:
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that it has been selected ... of only three finalists for a 2015 Tekne ... category. The Tekne Awards honor Minnesota ... and leadership. iMedNet™ eClinical  technology ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... ... November 24, 2015 , ... ... metabolism. But unless it is bound to proteins, copper is also toxic to ... researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper ...
(Date:11/24/2015)... PA (PRWEB) , ... November 24, 2015 , ... This ... entrepreneurs at competitive events in five states to develop and pitch their BIG ideas ... projects from each state are competing for votes to win the title of SAP's ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) ... remaining 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) ... B Warrants") subject to the previously disclosed November ... 2015, which will result in the issuance of ... the issuance of such shares, there will be ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW Telbec/ - ProMetic Life Sciences ... today that Mr. Pierre Laurin , President and Chief ... at the upcoming Piper Jaffray 27 th Annual Healthcare ... on December 1-2, 2015. st , at ... one-on-one meetings throughout the day. The presentation will be available ...
Breaking Biology Technology: